4DMT’s CF Drug Advances to Phase 2 with Foundation Support
Enrollment is underway in the Phase 2 stage of 4D Molecular Therapeutics’ AEROW trial with 2.5E14 vg set as...
Hutchmed to Present FRUSICA-2 Trial Data at ESMO Congress
Topline: In the Phase III FRUSICA-2 study (n=234) in second-line advanced renal cell carcinoma, fruquintinib plus sintilimab achieved a...
AdvanCell’s New Alpha Therapy Shows Promise for Prostate Cancer
AdvanCell’s ESMO abstract reports favorable safety and early anti-tumor activity for ADVC001, a Lead-212 (212Pb)-labeled PSMA radioligand, across seven...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...
Brepocitinib Poised to Fill Dermatomyositis Treatment Gap
The Phase 3 VALOR trial of brepocitinib in dermatomyositis has completed enrollment and is powered on the Total Improvement...
Assembly Bio Presents Interim Data on HSV Inhibitor ABI-5366
Interim Phase 1b data for Assembly Bio’s oral helicase-primase inhibitor ABI-5366 showed statistically significant reductions in key virologic and...
Rese-cel Shows Biologic Activity, No Preconditioning Needed
In three evaluable patients with pemphigus vulgaris (PV) treated with rese-cel at 1 x 10^6 cells/kg without preconditioning, Cabaletta...
New Study Advances Independence for People with Vision Loss
Two of three augmented-reality headsets evaluated in a peer-reviewed study of people with low vision delivered measurable gains in...
Positive Phase 2 Data for Alterity’s Parkinson’s Drug ATH434
ATH434 reduced disease progression on the modified UMSARS Part I at 52 weeks with a 48% relative treatment effect...
Pharma Unveils B-FREE Trial for Chronic Babesiosis Study
Phase 2 open-label study in chronic babesiosis will test a 90-day tafenoquine regimen with a primary patient-reported fatigue endpoint...